Hyperactivity News and Research

RSS

Brain function variations may increase person's risk of drug abuse

One can look at drug addiction as a moral issue, a social ill, or a criminal problem. But Lynn Oswald's experience studying the neuroscience of addiction tells her that it is something else entirely: a disease of the brain.

30 Apr 2011

Positive results from Shire's Vyvanse clinical trial in schizophrenia

Shire plc, the global specialty biopharmaceutical company, today announced positive results from a signal-finding study of Vyvanse(R) Capsules assessing its effect in a prospective examination of adults with negative symptom predominant schizophrenia.

28 Apr 2011

Unintentional prescription opioid overdose deaths have reached epidemic proportions in the U.S.

Unintentional overdose deaths in teens and adults have reached epidemic proportions in the U.S. In some 20 states in 2007 the number of unintentional drug poisoning deaths exceeded either motor vehicle crashes or suicides, two of the leading causes of injury death.

26 Apr 2011

KemPharm to formulate and develop KP106 as oral film dosage for ADHD treatment

KemPharm, Inc. today announced that KP106, its clinical candidate for Attention Deficit/Hyperactivity Disorder, will be formulated and developed in an oral film dosage form pursuant to an exclusive collaboration agreement with MonoSol Rx relating to the development, commercialization and manufacture of KP106.

26 Apr 2011

Curemark CM-182 demonstrates positive results for schizophrenia in transgenic chakragati model of psychosis

Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced today that its compound CM-182 demonstrated positive results for schizophrenia in the transgenic chakragati (ckr) model of psychosis. The mouse model screening was performed by the Contract Research Organization, Cerca Insights.

25 Apr 2011

MonoSol Rx, KemPharm enter development and commercialization partnership for ADHD prodrug

MonoSol Rx, LLC, the developer of PharmFilm® drug delivery technology, today announced that the Company has entered into a development and commercialization partnership with KemPharm, a biopharmaceutical company focused on the discovery and development of new, safer therapies for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), pain, and cardiovascular disease.

25 Apr 2011

Mindfulness meditation may enhance mental abilities

The positive effects of mindfulness meditation on pain and working memory may result from an improved ability to regulate a crucial brain wave called the alpha rhythm.

22 Apr 2011

Parks and green environments impact social, psychological and physical health outcomes

Research shows that a walk in the park is more than just a nice way to spend an afternoon. It's an essential component for good health, according to University of Illinois environment and behavior researcher Frances "Ming" Kuo.

20 Apr 2011

Scientists identify gene influencing levels of alcohol consumption

Scientists have identified a gene that appears to play a role in regulating how much alcohol people drink, in a study of over 47,000 people published today in Proceedings of the National Academy of Sciences.

5 Apr 2011

National Alliance for Research on Schizophrenia and Depression is now Brain & Behavior Research Foundation

The Brain & Behavior Research Foundation (formerly NARSAD, the National Alliance for Research on Schizophrenia and Depression) continues its 25-year mission to alleviate the suffering of mental illness by awarding grants that will lead to advances and breakthroughs in scientific research.

5 Apr 2011

Acamprosate can help treat patients with autism, Fragile X syndrome

In small, early clinical trials, adults and children with autism and Fragile X syndrome have shown improved communication and social behavior when treated with acamprosate, according to Craig Erickson, M.D., assistant professor of psychiatry at the Indiana University School of Medicine and chief of the Riley Hospital for Children Christian Sarkine Autism Treatment Center at Indiana University Health.

5 Apr 2011

Children with DCD tend to feel more emotionally isolated, less coherent and less optimistic

Attention Deficit Hyperactivity Disorder, or ADHD, is widely recognized by the medical community, and there are a number of therapies in place. But as many as six percent of all children suffer from the less familiar Developmental Coordination Disorder (DCD). Demonstrating a lack of refined motor skills, children with DCD tend to have a more difficult time playing sports and staying organized at school. They appear to be uncoordinated - and many parents think they'll grow out of it. But research shows that may not be true.

5 Apr 2011

Children with ASDs benefit from certain medical and behavioral treatments

Some medical and behavioral treatments show promise for reducing certain behaviors in children with autism spectrum disorders, but more research is needed to assess the potential benefits and harms, according to a new report funded by HHS' Agency for Healthcare Research and Quality. The research results were published online in the journal Pediatrics.

5 Apr 2011

Early recognition and treatment can control obsessive-compulsive manifestation

Obsessive-compulsive disorder is often diagnosed too late in children and adolescents. In the current issue of Deutsches Ärzteblatt International, Susanne Walitza and her colleagues point out that appropriate early recognition and treatment can positively affect the course of the disease.

1 Apr 2011

FDA panel to decide regarding food dyes and hyperactivity

A Food and Drug Administration panel is opening a two-day meeting on the link between artificial food dyes and hyperactivity in children. These dyes are used to color the cereals and snacks for children.

30 Mar 2011

Positive top-line results from Targacept's TC-5619 Phase 2 trial in adults with ADHD

Targacept, Inc today announced top-line results from a Phase 2 proof of concept trial of TC-5619 as a treatment for adults with attention deficit/hyperactivity disorder.

25 Mar 2011

Children with epilepsy more likely to have psychiatric symptoms

A newly published report reveals that children with epilepsy are more likely to have psychiatric symptoms, with gender a determining factor in their development.

25 Mar 2011

Early smoking onset linked to higher risk of cannabis use

Young people who start smoking at an early age have a much higher risk of starting to use cannabis by the time they turn 17. Risk factors that increase the likelihood of starting to smoke include externalising problem behaviours such as impulsiveness. Smoking, in turn, is a significant risk factor for cannabis use. These results have been confirmed in a project researching smoking at an early age and externalising behaviour as predictors of drug use.

23 Mar 2011

BioMarin announces preliminary results from ADAPT in patients suffering from PKU

BioMarin Pharmaceutical Inc. announced today preliminary results from ADAPT (A Diversified Approach for PKU Treatment) in an abstract (Abstract #91, Mental Health Screening in Phenylketoniuria Clinic) presented by Barbara Burton, MD at the 2011 annual American College of Medical Genetics conference in Vancouver, Canada.

19 Mar 2011

Special report takes critical look at debates about pediatric problematic moods, behaviors

Decisions about whether and how to diagnose children with emotional and behavioral disturbances, and whether and how to treat them, are sometimes not clear-cut. When decisions lie within a "zone of ambiguity," people who emphasize different value commitments can reach different but equally respectable conclusions.

17 Mar 2011

Hyperactivity News and Research

Brain function variations may increase person's risk of drug abuse

Positive results from Shire's Vyvanse clinical trial in schizophrenia

Unintentional prescription opioid overdose deaths have reached epidemic proportions in the U.S.

KemPharm to formulate and develop KP106 as oral film dosage for ADHD treatment

Curemark CM-182 demonstrates positive results for schizophrenia in transgenic chakragati model of psychosis

MonoSol Rx, KemPharm enter development and commercialization partnership for ADHD prodrug

Mindfulness meditation may enhance mental abilities

Parks and green environments impact social, psychological and physical health outcomes

Scientists identify gene influencing levels of alcohol consumption

National Alliance for Research on Schizophrenia and Depression is now Brain & Behavior Research Foundation

Acamprosate can help treat patients with autism, Fragile X syndrome

Children with DCD tend to feel more emotionally isolated, less coherent and less optimistic

Children with ASDs benefit from certain medical and behavioral treatments

Early recognition and treatment can control obsessive-compulsive manifestation

FDA panel to decide regarding food dyes and hyperactivity

Positive top-line results from Targacept's TC-5619 Phase 2 trial in adults with ADHD

Children with epilepsy more likely to have psychiatric symptoms

Early smoking onset linked to higher risk of cannabis use

BioMarin announces preliminary results from ADAPT in patients suffering from PKU

Special report takes critical look at debates about pediatric problematic moods, behaviors

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News